An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the
pharmacokinetics characteristics of DP-R208 (Candesartan cilexetil 8mg/Rosuvastatin 10mg), a
fixed dose combination compared with coadministration of separate constituents in healthy
adult volunteers